With the expanding of population, the pharmaceutical market demand is fast growing, and the pharmaceutical industry enters the rapid developing period, during which, the pharmaceutical equipment industry has also started to develop fast. However, from the perspective of the entire macro-environment, the Chinese pharmaceutical equipment industry develops relatively slow although it started early, enterprise scales are overall small, and added value of products is low. Still, it is learned that the Chinese pharmaceutical equipment industry has achieved some development in recent years with support to the pharmaceutical equipment industry from China’s national policy and strict control of quality requirements: the market size is growing year by year, and the market concentration will further improve.
According to data of the In-depth Market Research and Investment Strategy Analysis and Research Report of the Pharmaceutical Equipment Industry 2017-2022 issued by Newsijie Industry Research Center, the market size of the Chinese pharmaceutical equipment industry grew from RMB 32.3 billion to RMB 67.3 billion from 2012 to 2016.
According to information, with the implementation of the new-edition GMP certification of China, China’s requirements for the pharmaceutical enterprises rise to the "equal stress on software and hardware": the new-edition GMP strengthens the data monitoring and management during the production, largely increases the aseptic production standard, and explicitly requires pharmaceutical enterprises to complete equipment replacement in 5 years to reach relevant requirements, which has promoted the new round of upgrading of the overall equipment of the pharmaceutical industry, leading to the large growth of the Chinese pharmaceutical equipment industry in terms of output value, sales revenue, and profits, etc.
Requirements of the pharmaceutical industry enterprises for pharmaceutical equipment continue to rise, update cycle of equipment shortens, and the pharmaceutical equipment overall develops towards automation and intelligence. According to an insider, the Chinese pharmaceutical equipment industry will enter the new stage of capacity adjustment and intelligent upgrading. Therefore, in order to stay vibrant and maintain sustainable development in the fierce competition, pharmaceutical equipment enterprises must constantly conduct technological innovation, timely adjust development strategy, innovate management mode, and watch closely the industry integration opportunities.
A core issue that Tang Yue at Truking Technology was thinking about for the pharmaceutical equipment industry is how to achieve workforce reduced and unmanned production. According to information, the intelligent factory built by Truking Smart Robot Company is aimed at furnishing pharmaceutical production enterprises with the total solutions.
"At the intelligent factory of Truking Smart Robot Company, the information system is the brain, industrial internet is the nerves, and automatic logistics system is the blood; each functional area is efficiently integrated, to achieve the operation intelligence of the entire factory," said Tang Yue. A dual-intelligent situation will form after the project is completed—intelligent products and intelligent production, and the factory will become one of the world’s first factories for intelligent production of pharmaceutical equipment.
The pharmaceutical robot and intelligent pharmaceutical factory strategy of Truking Technology has achieved productization at the level of smart robots, of which one sign is the birth of the aseptic filling system of smart robot—the first production system of pharmaceutical smart robot with independent intellectual property in China. Truking Technology is striving to construct the total solution, with the intelligent pharmaceutical factory including VRS, MES, WMS, and PLM, etc.
Pharmaceutical equipment industry ushers in the fantastic opportunity for development with the Industry 4.0 wave, and how to balance innovation and cost, and quality and price becomes the key to success of enterprises. According to a relevant person at the pharmaceutical investment department of JD Capital, there is gradually a batch of enterprises with strong R&D capacity, independent intellectual property, and strong competitiveness on the middle and high-end market forming in the Chinese pharmaceu...
(All Rights Reserved)